Consumer body backs proposed ban on pharmacies compounding Ozempic

Pharma News: The concerns raised by the Therapeutic Goods Administration (TGA) regarding the compounding of Novo Nordisk’s Ozempic (semaglutide) by pharmacists has been supported by the Consumers Health Forum of Australia (CHF). While understanding the rationale behind the proposed ban by the TGA, CHF emphasised the pressing supply issues faced by consumers, particularly those dependent on Ozempic for diabetes treatment.

CHF CEO, Dr Elizabeth Deveny, expressed the gravity of the situation. She said “What we are hearing from consumers is that ever since Ozempic has become better known as a rapid weight loss drug for celebrities, suddenly people living with conditions, like diabetes, who need the drug for medical purposes can’t get it. For some it’s almost like their supply has dried up overnight.”

The TGA has warned doctors and pharmacists to consider their individual legal and professional responsibilities in prescribing and dispensing ‘unapproved’ products such as compounded semaglutide.

The most high-profile telehealth company to provide compounded pharmacy products is the Woolworth’s-backed Eucalyptus, which owns the Pilot and Juniper brands.

“A complete ban on compounded semaglutide would be disproportionate while global shortages persist and would deny thousands of Australians access to medication that is changing their lives for the better,” Eucalyptus clinical director Dr Matt Vickers said.

Dr Deveny underscored the significance of awareness, cautioning that individuals obtaining compounded versions of medicines like Ozempic may inadvertently be purchasing unregulated products.

“Compounding pharmacies play a crucial role in our healthcare system, especially when tailored medications are required. However, in the case of mass distribution of Ozempic, the TGA is asserting that it poses risks,” she explained.

Novo Nordisk has declared some compounded versions up to one-third impure. The company has already initiated legal action against a few compounding pharmacies, accusing their products of being less potent and of containing impurities.

As the debate over Ozempic’s supply issues unfolds, the CHF is proposing solutions to strike a balance between public safety and uninterrupted access to the medicine. One key recommendation is the call for harmonising standards. CHF is urging the government to collaborate with state and territory governments in standardising and auditing compounding pharmacy services to enhance the safety and reliability of these services.

Recognising the global supply issues facing Ozempic, CHF is amplifying their call for action. They acknowledge the challenges posed by the medication’s global demand and encourage the Australian Government to intensify efforts. The aim is to secure a more substantial influx of Ozempic into the country, addressing concerns about potential shortages and ensuring a steady supply for those who rely on it for medical purposes.

In a bid to foster collaboration and address the complexities surrounding medicine shortages, CHF is also advocating for a roundtable discussion that includes consumers, industry representatives, and clinicians. The objective is clear: to comprehensively tackle the challenges at hand, bringing diverse perspectives to the table and working towards effective, sustainable solutions that prioritise both public safety and patient needs.

A proposed ban on compounding Ozempic is under consideration by the TGA, with a final decision to be made by June.

In reimagining healthcare across the entire patient journey, Health Industry Hub^TM is the only one-stop-hub uniting the diversity of the Pharma, MedTech, Diagnostics & Biotech sectors to inspire meaningful change.

The Health Industry Hub^TM content is copyright protected. Access is available under individual user licenses. Please click here to subscribe and visit T&Cs here.